Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-730-0 | CAS number: 12627-14-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity studies with the structural analogue substances silicic acid, sodium salt or disodium metasilicate ranging from 4 weeks to 180 days have been conducted in rats, mice and dogs. From these studies a NOAEL (90d) of 227 - 237 mg/kg bw/day can be derived for rats. The NOAEL (90d) for mice is 260 – 284 mg/kg bw/day. From a 2-year drinking water study in rats with lithium chloride a NOAEL of 15.3 mg lithium/kg bw/day corresponding to 219 mg silicic acid lithium salt (MR: 2.8)/kg bw/day was derived.
Key value for chemical safety assessment
Additional information
No experimental repeated dose toxicity data are available for silicic acid, lithium salt. Therefore read-across was applied from soluble silicates, which have been tested for long-term toxicity via the oral route.
Ito et al. conducted a 90-day oral toxicity study similar to OECD guideline 408. Rats (5/sex/group) were administered disodium metasilicate via drinking water in concentrations of 200, 600 and 1800 ppm. No clearly treatment-related effects were found. Thus, a NOAEL of >=1800 ppm corresponding to >=227 mg/kg bw/day for males and >=237 mg/kg bw/day for females was determined.
In another subchronic study similar to OECD 408, male and female mice were exposed to disodium metasilicate in the drinking water at concentrations of 300, 900 and 2700 ppm (males) and 333, 1000 and 3000 ppm (females), respectively (Sawai et al., 1980). Parameters examined were mortality, body weight, urinalysis, clinical chemistry, haematology, organ weights and histopathology. The relative puitary gland weight was significantly increased in dose groups compared to the control, statistically significant only in the highest dose group. Other effects occasionally observed were single incidences and not dose-dependent. Under the test conditions, the NOAEL was determined to be 1000 ppm (corresponding to 260 – 284 mg/kg bw/day).
Silicic acid, sodium salt has been tested in repeated oral dose toxicity studies in rats and dogs with exposures ranging from 28 days to 180 days.
No adverse effects were observed in male and female rats administered the test substance via drinking water in concentrations of 79 and 159 mg/kg bw/day for 180 days (Smith et al., 1973). Body weight and mortality were the only parameters monitored. Statistically significant differences in body weight between dose and control groups were observed, but these were small (6% or less), not consistent and not dose related.
In a subacute study similar to OECD 407, the only treatment-related effects observed in rats were polydipsia, polyuria and soft stools at 2400 mg silicic acid, sodium salt/kg bw/day (Newberne and Wilson, 1970). Beagle dogs exhibited gross renal cortical lesions, polydipsia, polyuria and soft stools when receiving 2400 mg silicic acid, sodium salt/kg bw/day via feed for 4 weeks (Newberne and Wilson, 1970). In histopathological examination irritation of the renal tubular epithelium followed by degenerative and regenerative changes and inflammatory cell infiltration into the interstitium was noted.
In conclusion, repeated dose toxicity studies with disodium metasilicate and silicic acid, sodium salt revealed a low toxicity for soluble silicates.
Since silicic acid, lithium salt contains depending on its molar ratio 3.4 - 7% lithium (MR: 2.8 - 6.3), which is assumed to be bioavailable after ingestion, the repeated dose toxicity of lithium was also taken into consideration for assessment.
In a 2-year study by Trautner et al. (1958), rats were administered lithium chloride via drinking water in concentrations of 47, 93, 140 and 233 mg/kg bw/day (corresponding to 7.6, 15.3, 22.9 and 38.2 mg lithium/kg bw/day). In the highest dose group food and water intake fell to about 50% of the normal within a few days and the rats became progressively drowsy and asocial on the 3rd to 5th day. Their gate was staggering and hesitant and at resting a fine muscular tremor and trembling was observed. Simultaneously, the animals lost weight. Death occurred within 2-3 weeks. The plasma lithium levels increased steadily: mean plasma concentrations were about 3 mM when the first changes in behaviour became apparent and exceeded 8mM just before death. Except for gross dehydration and fat loss, gross pathology revealed no macroscopic damage. Some animals receiving 22.9 mg lithium/kg bw/day lost weight progressively, became ill and died within 3-4 weeks with the same systems as animals in the highest dose group. Other animals maintained a stable condition after an initial weight loss up to 20%. Later, usually within 2-4 weeks, these rats suddenly became ill, lost further weight and died. Rats of the 15.3 mg/kg bw/day dose group with a plasma lithium level of 1.5 – 2 mM no effects in health or behaviour could be determined significantly different from control animals. Thus under the conditions of the test, a NOAEL of 15.3 mg lithium/kg bw/day corresponding to 219 mg silicic acid, lithium salt (MR: 2.8)/kg bw/day was derived.
Human data:
Lithium is used as therapeutic drug for treatment of manic depressions and bipolar disorders. Therapeutic serum concentrations are normally about 3.5 - 5.6 mg/L (0.5 - 0.8 mM), at 10 mg/L of blood, a person is mildly lithium poisoned, at 15 mg/L they experience confusion and speech impairment and at 20 mg/L lithium there is a risk of death (Aral and Vecchio-Sadus, 2008). Toxic effects, that may appear after prolonged therapeutic use may include neurological symptoms, change in kidney function, hypothyroidism and leucocytosis.
The primary target organ for lithium toxicity is the central nervous system. Neurologic effects occurring during prolonged therapy often include minor effects on memory, motor activity and associate productivity. Hand tremor is the most common neurological side effect (Opresko, 1995).
Renal toxicity during lithium treatment includes the polyuria-polydipsia syndrome. Some patients develop nephrogenic diabetes insipidus (NDI), which in most cases seems to be reversible. However a small group of patients my develop chronic renal insufficiency (Lagerkvist and Lindell, 2002).
Lithium also produces many metabolic changes. In terms of mineral metabolism, lithium competes with sodium, potassium, magnesium and calcium and displaces them from intracellular and bone sites in this progression. Interaction of toxic metals and essential elements in the kidneys has been demonstrated in biological and toxic aspects (Aral and Vecchio-Sadus, 2008).
Gastrointestinal disturbances such as nausea or diarrhoea are other common side effects of lithium treatment (Aral and Vecchio-Sadus, 2008).
Justification for classification or non-classification
Based on available data on repeated dose toxicity from read-across or surrogate substances, silicic acid, lithium salt does not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.